Cladribine (Leustatin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV, SC
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1993-02-26: Initial FDA approval for treatment of active hairy cell leukemia. (Based on Saven et al. 1998)

History of changes in EMA indication

  • 1993-02-26: EURD

Also known as

  • Generic names: 2-chlorodeoxyadenosine, 2-CdA
  • Brand names: Leustatin, Litak, Movectro